A safety and feasibility study of the use of 670 nm red light in premature neonates

Kent, Alison; Broom, Margaret; Parr, V; Essex, Rohan W.; Abdel-Latif, Mohamed E; Dahlstrom, Jane E.; Valter, Krisztina; Provis, Jan; Natoli, Riccardo

doi:10.1038/jp.2015.5

Cited by 5 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of PBM therapy to treat pneumonia has been reported in 48 infants treated with conventional therapy who also received laser therapy with “Vostok” laser therapeutic devices for 2-3 days, compared to 45 infants receiving conventional therapy alone and another 18 healthy newborns as controls. In a trial of using red light therapy to treat retinopathy of prematurity [ 93 ], one notable side-effect was the survival of all 21 premature infants in the treatment group, while 4 infants in the non-treatment group died from lung complications (pers. com.…”

Section: Pbm In Airway Inflammation Gut Microbiome and Dysautonomiamentioning

confidence: 99%

A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19

Liebert¹,

Bicknell²,

Markman³

et al. 2020

Aging and disease

View full text Add to dashboard Cite

COVID-19 is an evolving pandemic that has far reaching global effects, with a combination of factors that makes the virus difficult to contain. The symptoms of infection can be devastating or at the least very debilitating for vulnerable individuals. It is clear that the elderly are at most risk of the adverse impacts of the virus, including hospitalization and death. Others at risk are those with comorbidities such as cardiovascular disease and metabolic conditions and those with a hyper-excitable immune response. Treatment options for those with acute responses to the virus are limited and there is an urgent need for potential strategies that can mitigate these severe effects. One potential avenue for treatment that has not been explored is the microbiome gut/lung axis. In addition to those severely affected by their acute reaction to the virus, there is also a need for treatment options for those that are slow to recover from the effects of the infection and also those who have been adversely affected by the measures put in place to arrest the spread of the virus. One potential treatment option is photobiomodulation (PBM) therapy. PBM has been shown over many years to be a safe, effective, non-invasive and easily deployed adjunctive treatment option for inflammatory conditions, pain, tissue healing and cellular energy. We have also recently demonstrated the effectiveness of PBM to alter the gut microbiome. PBM therapy is worthy of consideration as a potential treatment for those most vulnerable to COVID-19, such as the elderly and those with comorbidities. The treatment may potentially be advantageous for those infected with the virus, those who have a slow recovery from the effects of the virus and those who have been denied their normal exercise/rehabilitation programs due to the isolation restrictions that have been imposed to control the COVID-19 pandemic.

show abstract

Section: Pbm In Airway Inflammation Gut Microbiome and Dysautonomiamentioning

confidence: 99%

A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19

Liebert¹,

Bicknell²,

Markman³

et al. 2020

Aging and disease

View full text Add to dashboard Cite

show abstract

A pilot randomised clinical trial of 670 nm red light for reducing retinopathy of prematurity

et al. 2019

View full text Add to dashboard Cite

Cone Rescue with Laser Photobiomodulation in Murine and Human Retinal Dystrophy

Jpm

et al. 2021

Preprint

View full text Add to dashboard Cite

Retinitis pigmentosa (RP) encompasses a genetically diverse group of blinding inherited retinal diseases. In most subtypes the gene defect is expressed in the rod photoreceptors, yet in many affected individuals the cone photoreceptors undergo secondary degeneration, leading to loss of the remaining central vision. There is evidence that bioenergetic and oxidative stress are involved in this secondary cone loss. Photobiomodulation (PBM) uses low energy light in the far red or near-infrared spectrum to manipulate cellular activity. We have used a novel slit lamp-mounted retinal PBM laser to deliver precise energy levels to targeted retina. We showed that PBM laser attenuates oxidative and bioenergetic stress-induced photoreceptor loss in vitro and rescues cones in the rd1 murine model of RP. In a phase I trial (ACTRN12618000651280), foveal laser treatment was safe in humans with RP and temporarily recovered, on average, 5 letters of visual acuity.

show abstract

A safety and feasibility study of the use of 670 nm red light in premature neonates

Abstract: 670 nm red light appears to be a safe and feasible treatment for further research in respect to ROP.

Cited by 5 publications

References 37 publications

A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19

A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19

A pilot randomised clinical trial of 670 nm red light for reducing retinopathy of prematurity

Cone Rescue with Laser Photobiomodulation in Murine and Human Retinal Dystrophy

Contact Info

Product

Resources

About